

CSA 050820L

May 8, 2020

As part of the FFCRA and (CARES) Act, the U.S. Department of Health and Human Services (HHS), will provide claims reimbursement to health care providers generally at Medicare rates for testing uninsured patients for COVID-19 and treating uninsured patients with a COVID-19 diagnosis. The Health Resources & Services Administration (HRSA) has contracted with UnitedHealth Group to be the sole administrator of the HRSA COVID-19 Uninsured Program.

Reimbursement under this program will be made for qualifying testing for COVID-19 and treatment services with a primary COVID-19 diagnosis, as determined by HRSA (subject to adjustment as may be necessary), which include the following:

i. Specimen collection, diagnostic and antibody testing, and more. HRSA details can be found at: <https://www.hrsa.gov/CovidUninsuredClaim>.

This plan is billable via Change Healthcare for non-pharmacy providers as of Wednesday, May 6, 2020, and more specifically will be available via our MedRx platform as of Friday, May 8, 2020, *pending confirmation from the program administrator* that pharmacies/pharmacists are eligible for claims reimbursement.

3. NCPDP announces the availability of urgent industry guidance to aid pharmacists in expanding COVID-19 testing across the country.

Click [here](#) to access the NCPDP Emergency Preparedness Information Version 1.7 document.

Please note Payers continue to evaluate these billing requirements to establish the appropriate

